A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells
- PMID: 20042573
- DOI: 10.4049/jimmunol.0902033
A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells
Abstract
Bispecific Abs offer new perspectives for cancer immunotherapy. In this study, we describe a recombinant bispecific single-chain fragment variable (bsscFv) directed against Fc alpha RI (CD89) on polymorphonuclear neutrophils (PMNs) or monocytes/macrophages and HLA class II on lymphoma target cells. Fc alpha RI and HLA class II-directed single-chain fragment variable (scFv) fragments were isolated from phage display libraries, established from the hybridomas A77 and F3.3, respectively. The two scFv molecules were connected with a 20 aa flexible linker sequence. After expression in SF21 insect cells and chromatographic purification, the bispecific molecule showed specific binding to both Ags at K(D) values of 148 +/- 42 nM and 113 +/- 25 nM for the anti-Fc alpha RI and anti-HLA class II scFv components in the bsscFv, respectively. In Ab-dependent cytotoxicity assays with PMNs as effectors and a series of lymphoma-derived cell lines (ARH-77, RAJI, REH, NALM-6, RS4;11), the bsscFv was significantly more cytotoxic than the parental murine IgG1 and its chimeric IgG1 derivative. When targeting primary tumor cell isolates from six patients with B cell malignancies, the killing capacity of the (Fc alphaRI x HLA class II) bsscFv compared favorably to conventional HLA class II mAb. Importantly, the cell lines NALM-6 and RS411, as well as two primary tumor cell isolates, were exclusively lysed by the bsscFv. To our knowledge, this is the first report of an Fc alpha RI-directed bsscFv effectively recruiting PMNs for redirected cytotoxicity against human B cell malignancies. Our data show that an (Fc alpha RI x HLA class II) bsscFv is an interesting candidate for further engineering of small, modular immunopharmaceuticals.
Similar articles
-
A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.Br J Haematol. 2004 Apr;125(2):167-79. doi: 10.1111/j.1365-2141.2004.04893.x. Br J Haematol. 2004. PMID: 15059139
-
Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.J Immunol. 1998 Feb 15;160(4):1677-86. J Immunol. 1998. PMID: 9469424
-
Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.Cancer Res. 1998 Jul 15;58(14):3051-8. Cancer Res. 1998. PMID: 9679970
-
G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).J Hematother. 1995 Oct;4(5):415-21. doi: 10.1089/scd.1.1995.4.415. J Hematother. 1995. PMID: 8581378 Review.
-
Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.Biotechnol J. 2012 Dec;7(12):1444-50. doi: 10.1002/biot.201200250. Epub 2012 Nov 1. Biotechnol J. 2012. PMID: 23125076 Review.
Cited by
-
CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.Oncoimmunology. 2017 Oct 12;7(1):e1380142. doi: 10.1080/2162402X.2017.1380142. eCollection 2017. Oncoimmunology. 2017. PMID: 29296544 Free PMC article.
-
Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.Oncotarget. 2017 Jun 13;8(24):39356-39366. doi: 10.18632/oncotarget.17000. Oncotarget. 2017. PMID: 28454118 Free PMC article.
-
Tumor-Mediated Neutrophil Polarization and Therapeutic Implications.Int J Mol Sci. 2022 Mar 16;23(6):3218. doi: 10.3390/ijms23063218. Int J Mol Sci. 2022. PMID: 35328639 Free PMC article. Review.
-
Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.J Clin Invest. 2021 Mar 15;131(6):e134680. doi: 10.1172/JCI134680. J Clin Invest. 2021. PMID: 33561014 Free PMC article.
-
Novel antibody-based proteins for cancer immunotherapy.Cancers (Basel). 2011 Aug 19;3(3):3370-93. doi: 10.3390/cancers3033370. Cancers (Basel). 2011. PMID: 24212958 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous